Clinical trials: Scleroderma, Localized
Morphea, Plaque Form
Study to Assess Sarilumab in Halting Progression of Morphea
An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.
- Trial name
- NCT03679845
- Testing
- Sarilumab
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Generalized Morphea
Adult-onset Generalized Morphea
This study aimed to describe the demographical and clinical characteristics of a retrospective cohort of adult-onset GM and to investigate whether these findings differ between patients with an isomorphic and a symmetric pattern…
- Trial name
- MORPHEA (NCT04264728)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Scleroderma, Localized, Morphea
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country.
- Conditions
- Scleroderma, Localized, Morphea, Frontal Linear Scleroderma en Coup de Sabre, Scleroderma, Circumscribed
- Trial name
- MAC (NCT01808937)
- Testing
- Morphea
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Autoimmune Diseases, Sickle Cell Disease
Microvascular and Fibrosis Imaging Study
In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical Coherence Tomography (OCT) will be used to assess…
- Conditions
- Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
- Trial name
- NCT01758250
- Testing
- Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Duke University
Morphea, Scleroderma, Localized
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and…
- Conditions
- Morphea, Scleroderma, Localized, Scleroderma
- Trial name
- NCT03740724
- Testing
- FCX-013, veledimex
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Castle Creek Biosciences, LLC.
Localized Scleroderma
Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma
The study aims at evaluating the efficacy of the fractional carbon dioxide laser as a new modality for treatment of localized scleroderma and to compare its results with the well established method of UVA 1 phototherapy.
- Trial name
- NCT02002897
- Testing
- Fractional carbon dioxide laser, Ultraviolet A1 phototherapy (UVA1)
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Cairo University
Scleroderma, Keloids
UVA1 Light for Treatment of Scleroderma and Similar Conditions
The purpose of this investigation is to evaluate the effectiveness of an investigational device which is similar in appearance to a "tanning bed" but which emits ultraviolet irradiation of a specific wavelength known as UVA1.
- Conditions
- Scleroderma, Keloids, Other Fibrosing Conditions
- Trial name
- NCT00476801
- Testing
- German manufactured UVA1 light emitting device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Michigan
Localized Scleroderma
Photobiomodulation in Children With Localized Scleroderma
to evaluate the efficacy of the Polarized light therapy and Hand Grip Strengthening exercises in patients with CREST syndrome
- Trial name
- NCT06621628
- Testing
- Study Group A, Study GrouB, Study Group C
- Where
- 2 sites in Egypt
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- New Ismailia National University
Scleroderma, Systemic, Morphea
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
The purpose of this study is to assess the degree of improvement seen patient reported outcomes after 30 sessions of UVA-1 therapy in treating systemic scleroderma, morphea, and sclerodermatous Graft-Versus-Host Disease.
- Conditions
- Scleroderma, Systemic, Morphea, Graft Vs Host Disease
- Trial name
- NCT04922736
- Testing
- UVA-1 Phototherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
CREST Syndrome, Calcinosis Cutis
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas.
- Conditions
- CREST Syndrome, Calcinosis Cutis, Raynaud Phenomenon
- Trial name
- NCT03972566
- Testing
- INOMAX
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- RoseLab Skin Optics Laboratory
Systemic Sclerosis (SSc), Scleroderma
Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Physical functionality and performance are important for individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial…
- Conditions
- Systemic Sclerosis (SSc), Scleroderma, Scleroderma (Limited and Diffuse), Scleroderma, Localized
- Trial name
- NCT07183072
- Testing
- Questionnaire and functionality application for child and adult scleroderma patients
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hacettepe University
Microstomia, Scleroderma
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
The principal objective is to measure the degree to which oral microstomia caused by sclerosing skin disease improves after treating patients with local hyaluronidase injections.
- Conditions
- Microstomia, Scleroderma, CREST Syndrome, Scleromyxedema
- Trial name
- NCT04656704
- Testing
- hyaluronidase injected intradermally
- Sponsor
- Brigham and Women's Hospital
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Scleroderma
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being.
- Trial name
- NCT06880627
- Testing
- Brain Boost group, Waitlist group
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Michigan
Morphea (Circumscribed Scleroderma), Sclerotic Graft-versus-host Disease (GVHD)
Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease
This is a prospective, intra-individual comparative study to evaluate the effectiveness of local-water filtered infrared-A (wIRA) irradiation (applied by Hydrosun® radiator 750 for radiation at the clinic, or Hydrosun® 575home…
- Trial name
- NCT04954573
- Testing
- infrared-A (wIRA)
- Where
- 2 sites in Austria
- Volunteers
- 11 people
- Sponsor
- Medical University of Graz
Symmetric Limited Morphea
Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.
- Trial name
- NCT00812188
- Testing
- Medium Dose UVA-1, High Dose UVA-1
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Keloid, Scleroderma
UVA1 Light for Scleroderma and Similar Conditions
The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1 irradiation in the treatment of fibrosing conditions of the skin, e.g., keloid (a thick scar from growth of fibrous tissue), scleroderma…
- Conditions
- Keloid, Scleroderma, Scars, Granuloma Annulare
- Trial name
- NCT00476697
- Testing
- German manufactured UVA1 emitting light system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Fat Grafting, Hair Transplantation
Study on the Efficacy of Autologous Fat Grafting in Improving Hair Transplantation Outcomes for Patients With Localized Scleroderma-Related Alopecia
Investigating the efficacy and safety of autologous fat grafting combined with hair transplantation for the treatment of hair loss in patients with localized scleroderma."
- Conditions
- Fat Grafting, Hair Transplantation, Localized Scleroderma
- Trial name
- NCT06646146
- Testing
- Fat grafting combine with hair transplantation, Hair transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Scleroderma
Elastography Ultrasound in Localized Scleroderma (Morphea) Study
Localized scleroderma (LS) is a skin disease that can cause complications such as disfigurement and limitation of mobility. Treatment for LS should be initiated early in the disease, as late-stage scleroderma does not respond…
- Trial name
- NCT06847750
- Testing
- Elastography Ultrasound, The Localized Scleroderma Quality of Life Instrument (LoSQI )
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Scleroderma
Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
This is a study designed to evaluate the comparative effectiveness of topical medications for the treatment of circumscribed morphea.
- Trial name
- NCT02680717
- Testing
- Clobetasol, Calcipotriene, Tacrolimus
- Sponsor
- Medical College of Wisconsin